BioSpace News Archive

BioInvent International AB announces that Pfizer Inc. has selected the first target under the companies’ cancer immunotherapy research collaboration and license agreement, into which the companies entered in December 2016 to develop antibodies targeting tumor-associated myeloid cells.

Neuralstem, Inc. (Nasdaq: CUR) (“Neuralstem” or the “Company”) today announced the closing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit resulting in gross proceeds of approximately $7,500,000, before deducting discount, commissions and estimated offering expenses.

DisposeRx, a drug disposal company committed to eradicating the misuse of leftover medications in the home medicine cabinet, announced today its support and affirmation of a statement recently issued by the National Association of Chain Drug Stores (NACDS) regarding the key role of community pharmacies in helping to solve the opioid crisis

US Medical Innovations, LLC (USMI), a Biomedical and Life Science subsidiary of US Patent Innovations, LLC and the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS)™, LLC announced today that the U.S. Food and Drug Administration (FDA) has approved the first clinical trial in the U.S. to evaluate Cold Atmospheric Plasma (CAP) Technology for the treatment of cancer.

Have you ever heard the phrase, “worse than a root canal?” Chances are you have, but thanks likely to modern advancements in technology and the advanced training of root canal specialists known as endodontists, it turns out that cliché analogy may not ring as true as you think.

The nation’s top-ranked hospital for orthopedics announced a major new location opening in New York City in August 2019.

The global ENT laser devices market is expected to post a CAGR of more than 6% during the period 2019-2023, according to the latest market research report by Technavio.

MediBeacon and Huadong Medicine will collaboratively work to reach regulatory approval on MediBeacon’s entire portfolio of assets in Greater China [31-July-2019] ST. LOUIS , July 31, 2019 /PRNewswire/ -- MediBeacon Inc ., whose largest shareholder is Pansend Life Sciences, LLC, a subsidiary of HC2 Holdings, Inc. (NYSE MKT: HCHC), announced today that they have entere

Benitec Biopharma, a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference platform combining RNA interference with gene therapy, announced its Appendix 4C for the quarter ending 31 July 2019.

UrologyLocums.com announced today the launch of the company, adding a new player to the Locums Tenens arena.